Free Trial

Verona Pharma Q2 2023 Earnings Report

Verona Pharma logo
$62.70 -1.81 (-2.81%)
As of 03/28/2025 04:00 PM Eastern

Verona Pharma EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.16
One Year Ago EPS
N/A

Verona Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Verona Pharma Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Verona Pharma Earnings Headlines

Your Wealth is Under Attack
Please don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your free gift, and see how Trump's victory could spark major gains for gold.
See More Verona Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Verona Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verona Pharma and other key companies, straight to your email.

About Verona Pharma

Verona Pharma (NASDAQ:VRNA), a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

View Verona Pharma Profile

More Earnings Resources from MarketBeat